eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF
eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce Clinically Relevant PostOperative Pancreatic Fistula: A Phase 2 Randomized Control Trial (X-POPF)
Sponsor: Case Comprehensive Cancer Center
Terminated
Principal investigator left the institution.
Other terminated trials from Case Comprehensive Cancer Center
Listed as NCT05753735, this PHASE2 trial focuses on Pancreatic Fistula and remains terminated or withdrawn. Sponsored by Case Comprehensive Cancer Center, it has been updated 6 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Oct 2024 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE2
▶ Show 1 earlier version
-
Apr 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Case Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .